Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Yarrow Bioscience Inc(YARW)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for YARW
10/01/2026: YARW (2-star) is currently NOT-A-BUY. Pass it for now.
Yarrow Bioscience is a clinical-stage biotechnology company focused on treating Graves' disease and thyroid eye disease through its lead monoclonal antibody, YB-101. The company has successfully raised significant capital and completed a merger with VYNE Therapeutics, providing a cash runway that extends into 2028. Its primary investment story hinges on the success of its Phase 2 clinical trials, which aim to prove the efficacy of YB-101 as a potential first-in-class therapy. However, the company remains speculative, carrying high execution and competitive risks due to its single-asset pipeline. It is best suited for growth-oriented investors willing to accept volatility in exchange for potential breakthroughs in autoimmune medicine.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is in an early-stage growth phase with significant potential clinical catalysts. |
| Momentum investor | Mixed fit | Momentum is highly dependent on clinical trial news flow and market reactions to financing updates. |
| Value investor | Weak fit | The company has no current earnings and is valued based on speculative clinical progress. |
| Dividend investor | Weak fit | The company is a pre-profit clinical-stage biotech and does not pay dividends. |
| Low-risk investor | Weak fit | The high volatility and clinical risk inherent in early-stage biotech are unsuitable for low-risk strategies. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to sharp movements based on clinical study data and financing news. |
| Valuation risk | High | Pricing depends heavily on long-term clinical assumptions rather than current cash flows. |
| Competition risk (autoimmune) | Medium / high | Competition from large-cap players with existing FDA-approved drugs poses a material challenge. |
| Business quality | Medium | The company is unproven, though it holds a potentially disruptive technology for a large market. |
| Dividend income | Low / none | No capital return program exists as all cash is reinvested into R&D. |
| Execution risk | High | Successfully transitioning YB-101 through Phase 2/3 trials is essential for survival. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 0.33% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/01/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 190.05M USD | Price to earnings Ratio - | 1Y Target Price 57 |
Price to earnings Ratio - | 1Y Target Price 57 | ||
Volume (30-day avg) 134.5K shares | Beta 2.07 | 52 Weeks Range 8.95 - 44.28 | Updated Date 10/01/2026 |
52 Weeks Range 8.95 - 44.28 | Updated Date 10/01/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Therapeutic R&D | Clinical-stage revenue from research partnerships and long-term valuation potential from drug candidates like YB-101. | The company currently makes essentially no money and relies entirely on external capital to fund the research of its future medicine. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 212.35M | Price to Sales(TTM) - |
Enterprise Value 212.35M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 8.44M | Shares Floating 1.75M |
Shares Outstanding 8.44M | Shares Floating 1.75M | ||
Percent Insiders 2.02 | Percent Institutions 26.02 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Yarrow Bioscience Inc
Exchange NASDAQ | Headquarters New York, NY, United States | ||
IPO Launch date 2018-01-25 | President, CEO & Director Ms. Rebecca Velez Frey Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.yarrowbioscience.com |
Full time employees 7 | Website https://www.yarrowbioscience.com | ||
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.